Compare AYTU & ATCH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AYTU | ATCH |
|---|---|---|
| Founded | N/A | 2022 |
| Country | United States | United States |
| Employees | N/A | 46 |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.4M | 29.6M |
| IPO Year | 2015 | 2024 |
| Metric | AYTU | ATCH |
|---|---|---|
| Price | $2.17 | $0.18 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $9.33 | $1.00 |
| AVG Volume (30 Days) | 41.7K | ★ 3.8M |
| Earning Date | 05-13-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.02 |
| Revenue | ★ $27,632,080.00 | $20,052,635.00 |
| Revenue This Year | N/A | $84.47 |
| Revenue Next Year | $43.75 | $39.32 |
| P/E Ratio | ★ N/A | $9.39 |
| Revenue Growth | ★ 277.47 | 84.70 |
| 52 Week Low | $1.67 | $0.17 |
| 52 Week High | $3.07 | $0.61 |
| Indicator | AYTU | ATCH |
|---|---|---|
| Relative Strength Index (RSI) | 51.30 | 44.26 |
| Support Level | $2.21 | $0.18 |
| Resistance Level | $2.35 | $0.22 |
| Average True Range (ATR) | 0.13 | 0.02 |
| MACD | 0.03 | 0.00 |
| Stochastic Oscillator | 67.35 | 19.33 |
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates one business segment consisting of various prescription pharmaceutical products sold through third parties.
AtlasClear Holdings Inc is a fintech company. Its goal is to build a cutting-edge technology-enabled financial services firm that would create a more efficient platform for trading, clearing, settlement, and banking of evolving and financial products with a focus on financial services firms. It is a fintech-driven business-to-business platform that expects to power innovation in fintech, investing, and trading. The company believes it is positioned to provide a modern, mission-critical suite of solutions to its clients, enabling them to reduce their transaction costs and compete more effectively in their businesses.